Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
NMR Biomed ; 27(4): 431-43, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24493129

ABSTRACT

Proton magnetic resonance spectroscopy (MRS) is a sensitive method for investigating the biochemical compounds in a tissue. The interpretation of the data relies on the quantification algorithms applied to MR spectra. Each of these algorithms has certain underlying assumptions and may allow one to incorporate prior knowledge, which could influence the quality of the fit. The most commonly considered types of prior knowledge include the line-shape model (Lorentzian, Gaussian, Voigt), knowledge of the resonating frequencies, modeling of the baseline, constraints on the damping factors and phase, etc. In this article, we study whether the statistical outcome of a biological investigation can be influenced by the quantification method used. We chose to study lipid signals because of their emerging role in the investigation of metabolic disorders. Lipid spectra, in particular, are characterized by peaks that are in most cases not Lorentzian, because measurements are often performed in difficult body locations, e.g. in visceral fats close to peristaltic movements in humans or very small areas close to different tissues in animals. This leads to spectra with several peak distortions. Linear combination of Model spectra (LCModel), Advanced Method for Accurate Robust and Efficient Spectral fitting (AMARES), quantitation based on QUantum ESTimation (QUEST), Automated Quantification of Short Echo-time MRS (AQSES)-Lineshape and Integration were applied to simulated spectra, and area under the curve (AUC) values, which are proportional to the quantity of the resonating molecules in the tissue, were compared with true values. A comparison between techniques was also carried out on lipid signals from obese and lean Zucker rats, for which the polyunsaturation value expressed in white adipose tissue should be statistically different, as confirmed by high-resolution NMR measurements (considered the gold standard) on the same animals. LCModel, AQSES-Lineshape, QUEST and Integration gave the best results in at least one of the considered groups of simulated or in vivo lipid signals. These outcomes highlight the fact that quantification methods can influence the final result and its statistical significance.


Subject(s)
Algorithms , Lipids/chemistry , Magnetic Resonance Spectroscopy , Protons , Signal Processing, Computer-Assisted , Adipose Tissue, White/metabolism , Animals , Area Under Curve , Computer Simulation , Oils/chemistry , Rats , Rats, Zucker , Signal-To-Noise Ratio
2.
Magn Reson Med ; 62(4): 1080-4, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19725135

ABSTRACT

In activation-induced manganese-enhanced MRI (AIM-MRI) experiments, differential accumulation of Mn in activated and silent brain areas is generally assessed using T(1)-weighted images and quantified by the enhancement of signal intensity (SI), calculated with reference to SI before Mn administration or to SI of brain regions unaffected by the specific stimulus. However, SI enhancement can be unreliable when animals are removed from and reinserted into the magnet. We have developed an experimental protocol based on repeated intraperitoneal (i.p.) injections of Mn, quantitative determination of T(1), and coregistration of images to a rat brain atlas that allows absolute quantification of Mn concentration in selected brain areas. Results showed that interanimal variability of postcontrast T(1) values was very low (compared to the experimental error in T(1) determinations) allowing detection of differential regional Mn uptake in stimulated and unstimulated animals. In addition we have determined in vivo relaxivity of Mn in brain tissue and its frequency dependence.


Subject(s)
Brain Mapping/methods , Brain/anatomy & histology , Brain/physiology , Chlorides/pharmacokinetics , Image Interpretation, Computer-Assisted/methods , Magnetic Resonance Imaging/methods , Manganese Compounds/pharmacokinetics , Algorithms , Animals , Computer Simulation , Contrast Media/pharmacokinetics , Image Enhancement/methods , Male , Models, Neurological , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Sensitivity and Specificity
3.
Br J Sports Med ; 42(1): 42-6, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17526621

ABSTRACT

OBJECTIVE: The lower impact on the musculoskeletal system induced by plyometric exercise on sand compared to a firm surface might be useful to reduce the stress of intensified training periods or during rehabilitation from injury. The aim of this study was to compare the effects of plyometric training on sand versus a grass surface on muscle soreness, vertical jump height and sprinting ability. DESIGN: Parallel two-group, randomised, longitudinal (pretest-post-test) study. METHODS: After random allocation, 18 soccer players completed 4 weeks of plyometric training on grass (grass group) and 19 players on sand (sand group). Before and after plyometric training, 10 m and 20 m sprint time, squat jump (SJ), countermovement jump (CMJ), and eccentric utilization ratio (CMJ/SJ) were determined. Muscle soreness was measured using a Likert scale. RESULTS: No training surface x time interactions were found for sprint time (p>0.87), whereas a trend was found for SJ (p = 0.08), with both groups showing similar improvements (p<0.001). On the other hand, the grass group improved their CMJ (p = 0.033) and CMJ/SJ (p = 0.005) significantly (p<0.001) more than players in the sand group. In contrast, players in the sand group experienced less muscle soreness than those in the grass group (p<0.001). CONCLUSIONS: Plyometric training on sand improved both jumping and sprinting ability and induced less muscle soreness. A grass surface seems to be superior in enhancing CMJ performance while the sand surface showed a greater improvement in SJ. Therefore, plyometric training on different surfaces may be associated with different training-induced effects on some neuromuscular factors related to the efficiency of the stretch-shortening cycle.


Subject(s)
Muscle, Skeletal/physiopathology , Physical Education and Training/methods , Poaceae , Running/physiology , Silicon Dioxide , Soccer/physiology , Adult , Analysis of Variance , Humans , Pain/physiopathology
4.
Article in English | MEDLINE | ID: mdl-12570726

ABSTRACT

In the course of pregnancy amnion cells produce a number of factors which include cytokines and prostaglandins (PGs) produced in response to autocrine, paracrine and endocrine signals. Recent studies performed by several researchers contributed to elucidate the mechanism through which amnion tissue is involved in the triggering of physiological labor. However, there are other possible functions to be ascribed to amniotic cells, depending on the high number of factors that they produce as well as on the receptors that enable them to act in turn as target. For instance, it has been demonstrated that amnion cells are able to produce lecithin upon the regulation of several factors, such as glucocorticoids and epidermal growth factor, a finding that suggests a protective role of the tissue on fetal pulmonary function. As regards to triggering the uterine contractions, it is accepted that prostaglandin release by amnion cells represents a key event. It is under the control of hormones, growth factors, cytokines and probably PGs themselves. A striking analogy has been found between the mechanism of inflammation and the onset of myometrial activity in labor. In this context, it has been shown that for-Met-Leu-Phe (fMLP), the prototype of a series of formylated peptides traditionally considered chemotactic agents, is also involved in the regulation of amniotic PG release. The similitude between labor and inflammatory response is enforced by the antiprostaglandin action of some classes of antibiotics observed in amnion tissue, that enable them as effective tools against preterm labor, both in the absence and in the presence of infection. As for the mechanisms responsible for the regulation of PG synthesis, some agents act by influencing protein synthesis, while others exert their effects through the production of intracellular second messengers, mainly represented by phosphatidyl-inositol-4-5 bisphosphate and cyclic AMP. The mechanism whereby second messengers induce PG release is not clear, and a crosstalk between the two transduction pathways could be hypothesized. This interaction has extensively been analysed in "WISH" cells, a human amnion-derived cell line, which represent a model for the in vitro study of amnion functions. In the present review, we intend to report the results of the studies regarding the mechanisms through which the control of the above mentioned functions is executed.


Subject(s)
Amnion/cytology , Amnion/physiopathology , Cell Line , Amnion/metabolism , Cytokines/biosynthesis , Humans , Prostaglandins/biosynthesis
5.
Placenta ; 23(8-9): 575-83, 2002.
Article in English | MEDLINE | ID: mdl-12361677

ABSTRACT

In order to clarify the possible interactions between nitric oxide (NO) and arachidonic acid (AA) pathways, human amnion-like WISH cells were perifused to measure the effects of the following substances on [(3)H]arachidonic acid release: (1) sodium nitroprusside (SNP), a nitric oxide donor; (2) 1,1,1-trifluoromethyl-6,9,12,15-heicosatetraen-2-one, a cytosolic phospholipase A(2) (cPLA(2)) inhibitor; (3)L -arginine, the substrate of nitric oxide synthase (NOS); (4) 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole and 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one, activator and inhibitor of soluble guanylyl cyclase, respectively; (5) a membrane-permeable non-hydrolyzable analogue of guanosine-3',5'-cyclic monophosphate (cGMP). Furthermore, the effect of SNP on prostaglandin E(2) (PGE(2)) release was tested. Exogenous and endogenous NO, as well as the guanylyl cyclase activator and cGMP analogue, significantly increased [(3)H]arachidonic acid release. Both soluble guanylyl cyclase and PLA(2) inhibitors counteracted SNP response. Exogenous NO increased PGE(2) release, although to a much lesser degree compared with arachidonic acid release. Our results indicate that NO stimulates AA release in WISH cells by activating PLA(2) through a cyclic GMP-dependent mechanism.


Subject(s)
Amnion/metabolism , Arachidonic Acid/metabolism , Nitric Oxide/physiology , Amnion/cytology , Amnion/drug effects , Arginine/pharmacology , Cells, Cultured , Cyclic GMP/analogs & derivatives , Dinoprostone/metabolism , Dose-Response Relationship, Drug , Indazoles/pharmacology , Nitric Oxide/pharmacology , Nitroprusside/pharmacology , Oxadiazoles/pharmacology , Quinoxalines/pharmacology
6.
J Clin Endocrinol Metab ; 85(8): 2767-74, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10946879

ABSTRACT

Abdominal obesity and hyperinsulinemia play a key role in the development of the polycystic ovary syndrome (PCOS). Dietary-induced weight loss and the administration of insulin-lowering drugs, such as metformin, are usually followed by improved hyperandrogenism and related clinical abnormalities. This study was carried out to evaluate the effects of combined hypocaloric diet and metformin on body weight, fat distribution, the glucose-insulin system, and hormones in a group of 20 obese PCOS women [body mass index (BMI) > 28 kg/m2] with the abdominal phenotype (waist to hip ratio >0.80), and an appropriate control group of 20 obese women who were comparable for age and pattern of body fat distribution but without PCOS. At baseline, we measured sex hormone, sex hormone-binding globulin (SHBG), and leptin blood concentrations and performed an oral glucose tolerance test and computerized tomography (CT) at the L4-L5 level, to measure sc adipose tissue area (SAT) and visceral adipose tissue area. All women were then given a low-calorie diet (1,200-1,400 kcal/day) alone for one month, after which anthropometric parameters and CT scan were newly measured. While continuing dietary treatment, PCOS women and obese controls were subsequently placed, in a random order, on metformin (850 mg/os, twice daily) (12 and 8, respectively) or placebo (8 and 12, respectively), according to a double-blind design, for the following 6 months. Blood tests and the CT scan were performed in each woman at the end of the study while they were still on treatment. During the treatment period, 3 women of the control group (all treated with placebo) were excluded because of noncompliance; and 2 PCOS women, both treated with metformin, were also excluded because they became pregnant. Therefore, the women cohort available for final statistical analysis included 18 PCOS (10 treated with metformin and 8 with placebo) and 17 control women (8 treated with metformin and 9 with placebo). The treatment was well tolerated. In the PCOS group, metformin therapy improved hirsutism and menstrual cycles significantly more than placebo. Baseline anthropometric and CT parameters were similar in all groups. Hypocaloric dieting for 1 month similarly reduced BMI values and the waist circumference in both PCOS and control groups, without any significant effect on CT scan parameters. In both PCOS and control women, however, metformin treatment reduced body weight and BMI significantly more than placebo. Changes in the waist-to-hip ratio values were similar in PCOS women and controls, regardless of pharmacological treatment. Metformin treatment significantly decreased SAT values in both PCOS and control groups, although only in the latter group were SAT changes significantly greater than those observed during the placebo treatment. On the contrary, visceral adipose tissue area values significantly decreased during metformin treatment in both PCOS and control groups, but only in the former was the effect of metformin treatment significantly higher than that of placebo. Fasting insulin significantly decreased in both PCOS women and controls, regardless of treatment, whereas glucose-stimulated insulin significantly decreased only in PCOS women and controls treated with metformin. Neither metformin or placebo significantly modified the levels of LH, FSH, dehydroepiandrosterone sulphate, and progesterone in any group, whereas testosterone concentrations decreased only in PCOS women treated with metformin. SHBG concentrations remained unchanged in all PCOS women; whereas in the control group, they significantly increased after both metformin and placebo. Leptin levels decreased only during metformin treatment in both PCOS and control groups. (ABSTRACT TRUNCATED)


Subject(s)
Adipose Tissue/anatomy & histology , Androgens/blood , Body Composition , Diet, Reducing , Hypoglycemic Agents/therapeutic use , Insulin/blood , Metformin/therapeutic use , Obesity/therapy , Polycystic Ovary Syndrome/complications , Abdomen , Adult , Combined Modality Therapy , Double-Blind Method , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Humans , Leptin/blood , Luteinizing Hormone/blood , Obesity/complications , Obesity/physiopathology , Placebos , Polycystic Ovary Syndrome/physiopathology , Progesterone/blood , Sex Hormone-Binding Globulin/analysis , Viscera
7.
Haematologica ; 84(9): 824-8, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10477457

ABSTRACT

BACKGROUND AND OBJECTIVE: Hyperhomocysteinemia, due to a combination of genetic and environmental factors, is considered to be a risk factor for vascular disease. Individuals with the thermolabile variant of methylenetetrahydrofolate reductase (MTHFR), due to homozygous C677T MTHFR gene mutation, have significantly raised plasma levels of homocysteine and may be at increased risk of vascular disease. However, it is still controversial a direct association between C677T homozygosity and the occurrence of vascular disease is still controversial. DESIGN AND METHODS: To clarify the contribution of C677T MTHFR mutation in arterial occlusive disease (AOD) or venous thromboembolism (VTE), we performed a case-controlled study including 160 cases with AOD and 180 cases with VTE attending our referral center and compared them with 200 matched healthy controls. MTHFR gene mutation was evaluated by PCR and odds ratios (OR) and the 95% confidence intervals (CI) were used to estimate the risk for venous or arterial thrombosis. RESULTS: There was a high prevalence of homozygotes for the mutated MTHFR allele among the whole group of cases with arterial disease (OR = 2.35, p = 0.001). Considering the AOD cases with and those without associated risk factors for arterial disease separately the difference remained significant only in the latter group (p = 0.168 and P<0.001 respectively). In contrast, the prevalence of mutated homozygotes among the whole group of cases with VTE was not significantly different from that in the control group (OR = 1.67; p = 0.070). Excluding VTE cases with inherited thrombophilia or with circumstantial risk situations the value increased in both subgroups (OR = 2.26; p = 0.006 and OR = 2.03; p = 0.033 respectively). Considering only VTE cases with neither inherited thrombophilia nor circumstantial risk situations the risk increased further (OR = 2.57; p = 0.017). INTERPRETATION AND CONCLUSIONS: These data suggest that in selected patients homozygosity for the MTHFR mutation increases the risk of both arterial and venous thromboses and that differences in selection criteria for the patient group may be responsible in part for the controversial association of the MTHFR mutation and vascular disease.


Subject(s)
Arterial Occlusive Diseases/genetics , Hyperhomocysteinemia/genetics , Oxidoreductases Acting on CH-NH Group Donors/genetics , Point Mutation , Thrombophilia/genetics , Adult , Aged , Alleles , Amino Acid Substitution , Arterial Occlusive Diseases/epidemiology , Case-Control Studies , Female , Gene Frequency , Genetic Predisposition to Disease , Genetic Testing , Genotype , Humans , Hyperhomocysteinemia/epidemiology , Male , Methylenetetrahydrofolate Reductase (NADPH2) , Middle Aged , Myocardial Infarction/epidemiology , Myocardial Infarction/genetics , Odds Ratio , Risk Factors , Thrombophilia/epidemiology
8.
Horm Res ; 52(6): 291-4, 1999.
Article in English | MEDLINE | ID: mdl-10965210

ABSTRACT

Thyroid tuberculosis is rare. In the last decade, however, the incidence of extrapulmonary forms of tuberculosis has increased. We report on 2 cases of thyroid tuberculosis. In case 1, a tubercular abscess mimicking acute thyroiditis was found which was correctly diagnosed by fine-needle aspiration biopsy (FNAb). No evidence of active disease was noticed. Pleural thickening on chest X-ray was the only sign compatible with a previous infection. In case 2, tubercular thyroiditis with lymph node enlargement was also diagnosed by FNAb in a reevaluation setting. In both cases treatment with antitubercular drugs resulted in complete recovery. Thyroid tuberculosis should be kept in mind in the differential diagnosis of thyroid nodules, notably in patients with a history of tuberculous disease. FNAb represents the main approach to making the diagnosis.


Subject(s)
Thyroid Diseases/microbiology , Tuberculosis, Endocrine/diagnosis , Abscess/microbiology , Aged , Aged, 80 and over , Antitubercular Agents/therapeutic use , Biopsy, Needle , Ethambutol/therapeutic use , Female , Humans , Isoniazid/therapeutic use , Lymph Nodes/pathology , Mycobacterium tuberculosis/isolation & purification , Rifampin/therapeutic use , Thyroid Diseases/pathology , Tuberculosis, Endocrine/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...